6-MBPB
| File:6MBPB structure.png | |
| Clinical data | |
|---|---|
| Other names | 6-MABB; 6-(2-Methylaminobutyl)benzofuran |
| Drug class | Serotonin–norepinephrine–dopamine releasing agent; Entactogen |
| Identifiers | |
| |
| PubChem CID | |
| ChemSpider | |
| ChEMBL | |
| E number | {{#property:P628}} |
| CompTox Dashboard (EPA) |
|
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C13H17NO |
| Molar mass | 203.285 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
6-MBPB, also known as 6-(2-methylaminobutyl)benzofuran (6-MABB), is a monoamine releasing agent (MRA) and entactogen-like drug of the amphetamine, phenylisobutylamine, and benzofuran families.[1][2][3][4][5] It is a positional isomer of 5-MBPB (5-MABB).[1][2][3][4][5]
The drug appears to act as a serotonin–norepinephrine–dopamine releasing agent (SNDRA).[1][2] The EC50 values for induction of monoamine release in rat brain synaptosomes have been reported for the individual enantiomers of 6-MBPB.[2] In the case of (S)-6-MBPB, they were 54 nM for serotonin, 77 nM for norepinephrine, and 41 nM for dopamine, whereas for (R)-6-MBPB, they were 172 nM for serotonin, 227 nM for norepinephrine, and inactive for dopamine.[2] Hence, (S)-6-MBPB is an SNDRA, whereas (R)-MBPB is a serotonin–norepinephrine releasing agent (SNRA).[2] The enantiomers showed a mixed profile of acting as full versus partial releasers.[2] Unlike 5-MAPB, it is a relatively weak serotonin 5-HT1B receptor agonist.[6] 6-MBPB partially substituted for MDMA in animal drug discrimination tests at lower doses and fully substituted for MDMA at the highest dose, suggesting that it has entactogen-like effects.[1][2][4]
Along with 5-MBPB, 6-MBPB was patented by Matthew Baggott and Tactogen in 2021.[5] It was first described in the scientific literature by 2022.[3][4] 6-MBPB, along with other drugs like 5-MBPB, is being investigated as a novel MDMA-like drug for potential therapeutic purposes in medicine.[1][2]
See also
[edit | edit source]- Substituted benzofuran
- 5-MBPB (5-MABB)
References
[edit | edit source]- ^ a b c d e Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b c d e f g h i Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b c d Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ a b c Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
- ^ US 20230150963, Matthew Baggott, "Advantageous benzofuran compositions for mental disorders or enhancement", published Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value)., assigned to Tactogen